MovDisordV3, PascalFrancis, Corpus, bibRecord, 000293

Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism

Identifieur interne : 000293 ( PascalFrancis/Corpus ); précédent : 000292; suivant : 000294

Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism

Auteurs : Karin Srulijes ; Matthias Reimold ; Rajka M. Liscic ; Sarah Bauer ; Elisabeth Dietzel ; Inga Liepelt-Scarfone ; Daniela Berg ; Walter Maetzler

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0106517

Descripteurs français

Pascal (Inist)
- Parkinsonisme, Pathologie du système nerveux, Tomoscintigraphie, Tomographie par émission de positons, Ophtalmoplégie supranucléaire, Instabilité.

English descriptors

KwdEn :
- Emission tomography, Instability, Nervous system diseases, Parkinsonism, Positron emission tomography, Supranuclear ophthalmoplegia.

Abstract

Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism`
A11	`01`	`1`		`@1 SRULIJES (Karin)`
A11	`02`	`1`		`@1 REIMOLD (Matthias)`
A11	`03`	`1`		`@1 LISCIC (Rajka M.)`
A11	`04`	`1`		`@1 BAUER (Sarah)`
A11	`05`	`1`		`@1 DIETZEL (Elisabeth)`
A11	`06`	`1`		`@1 LIEPELT-SCARFONE (Inga)`
A11	`07`	`1`		`@1 BERG (Daniela)`
A11	`08`	`1`		`@1 MAETZLER (Walter)`
A14	`01`			`@1 Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen @2 Tuebingen @3 DEU @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen @2 Tuebingen @3 DEU @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut.`
A14	`03`			`@1 Nuclear Medicine and PET Center, University of Tuebingen @2 Tuebingen @3 DEU @Z 2 aut.`
A14	`04`			`@1 Robert-Bosch-Hospital, Department of Clinical Gerontology @2 Stuttgart @3 DEU @Z 8 aut.`
A20				`@1 151-155`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000508687520250`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 12-0106517`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B24B07`
C03	`01`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Tomoscintigraphie @5 09`
C03	`03`	`X`	`ENG`	`@0 Emission tomography @5 09`
C03	`03`	`X`	`SPA`	`@0 Tomocentelleografía @5 09`
C03	`04`	`X`	`FRE`	`@0 Tomographie par émission de positons @5 10`
C03	`04`	`X`	`ENG`	`@0 Positron emission tomography @5 10`
C03	`04`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 10`
C03	`05`	`X`	`FRE`	`@0 Ophtalmoplégie supranucléaire @5 11`
C03	`05`	`X`	`ENG`	`@0 Supranuclear ophthalmoplegia @5 11`
C03	`05`	`X`	`SPA`	`@0 Oftalmoplejía supranuclear @5 11`
C03	`06`	`X`	`FRE`	`@0 Instabilité @5 12`
C03	`06`	`X`	`ENG`	`@0 Instability @5 12`
C03	`06`	`X`	`SPA`	`@0 Inestabilidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Syndrome oculomoteur @5 39`
C07	`03`	`X`	`ENG`	`@0 Oculomotor syndrome @5 39`
C07	`03`	`X`	`SPA`	`@0 Oculomotricidad síndrome @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'oeil @5 40`
C07	`04`	`X`	`ENG`	`@0 Eye disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Ojo patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 41`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 41`
C07	`06`	`X`	`FRE`	`@0 Syndrome du tronc cérébral @5 43`
C07	`06`	`X`	`ENG`	`@0 Brain stem syndrome @5 43`
C07	`06`	`X`	`SPA`	`@0 Tallo encefalico sindrome @5 43`
N21				`@1 079`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 12-0106517 INIST
ET :	Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism
AU :	SRULIJES (Karin); REIMOLD (Matthias); LISCIC (Rajka M.); BAUER (Sarah); DIETZEL (Elisabeth); LIEPELT-SCARFONE (Inga); BERG (Daniela); MAETZLER (Walter)
AF :	Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen/Tuebingen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen/Tuebingen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Nuclear Medicine and PET Center, University of Tuebingen/Tuebingen/Allemagne (2 aut.); Robert-Bosch-Hospital, Department of Clinical Gerontology/Stuttgart/Allemagne (8 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 1; Pp. 151-155; Bibl. 25 ref.
LA :	Anglais
EA :	Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.
CC :	002B17; 002B24B07
FD :	Parkinsonisme; Pathologie du système nerveux; Tomoscintigraphie; Tomographie par émission de positons; Ophtalmoplégie supranucléaire; Instabilité
FG :	Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du système nerveux central; Syndrome du tronc cérébral
ED :	Parkinsonism; Nervous system diseases; Emission tomography; Positron emission tomography; Supranuclear ophthalmoplegia; Instability
EG :	Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome
SD :	Parkinson síndrome; Sistema nervioso patología; Tomocentelleografía; Tomografía emisión positrones; Oftalmoplejía supranuclear; Inestabilidad
LO :	INIST-20953.354000508687520250
ID :	12-0106517

Links to Exploration step

Pascal:12-0106517

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism</title>
<author><name sortKey="Srulijes, Karin" sort="Srulijes, Karin" uniqKey="Srulijes K" first="Karin" last="Srulijes">Karin Srulijes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reimold, Matthias" sort="Reimold, Matthias" uniqKey="Reimold M" first="Matthias" last="Reimold">Matthias Reimold</name>
<affiliation><inist:fA14 i1="03"><s1>Nuclear Medicine and PET Center, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liscic, Rajka M" sort="Liscic, Rajka M" uniqKey="Liscic R" first="Rajka M." last="Liscic">Rajka M. Liscic</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bauer, Sarah" sort="Bauer, Sarah" uniqKey="Bauer S" first="Sarah" last="Bauer">Sarah Bauer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dietzel, Elisabeth" sort="Dietzel, Elisabeth" uniqKey="Dietzel E" first="Elisabeth" last="Dietzel">Elisabeth Dietzel</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liepelt Scarfone, Inga" sort="Liepelt Scarfone, Inga" uniqKey="Liepelt Scarfone I" first="Inga" last="Liepelt-Scarfone">Inga Liepelt-Scarfone</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maetzler, Walter" sort="Maetzler, Walter" uniqKey="Maetzler W" first="Walter" last="Maetzler">Walter Maetzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Robert-Bosch-Hospital, Department of Clinical Gerontology</s1>
<s2>Stuttgart</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0106517</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0106517 INIST</idno>
<idno type="RBID">Pascal:12-0106517</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000293</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism</title>
<author><name sortKey="Srulijes, Karin" sort="Srulijes, Karin" uniqKey="Srulijes K" first="Karin" last="Srulijes">Karin Srulijes</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reimold, Matthias" sort="Reimold, Matthias" uniqKey="Reimold M" first="Matthias" last="Reimold">Matthias Reimold</name>
<affiliation><inist:fA14 i1="03"><s1>Nuclear Medicine and PET Center, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liscic, Rajka M" sort="Liscic, Rajka M" uniqKey="Liscic R" first="Rajka M." last="Liscic">Rajka M. Liscic</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bauer, Sarah" sort="Bauer, Sarah" uniqKey="Bauer S" first="Sarah" last="Bauer">Sarah Bauer</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dietzel, Elisabeth" sort="Dietzel, Elisabeth" uniqKey="Dietzel E" first="Elisabeth" last="Dietzel">Elisabeth Dietzel</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Liepelt Scarfone, Inga" sort="Liepelt Scarfone, Inga" uniqKey="Liepelt Scarfone I" first="Inga" last="Liepelt-Scarfone">Inga Liepelt-Scarfone</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berg, Daniela" sort="Berg, Daniela" uniqKey="Berg D" first="Daniela" last="Berg">Daniela Berg</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maetzler, Walter" sort="Maetzler, Walter" uniqKey="Maetzler W" first="Walter" last="Maetzler">Walter Maetzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Robert-Bosch-Hospital, Department of Clinical Gerontology</s1>
<s2>Stuttgart</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Emission tomography</term>
<term>Instability</term>
<term>Nervous system diseases</term>
<term>Parkinsonism</term>
<term>Positron emission tomography</term>
<term>Supranuclear ophthalmoplegia</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Pathologie du   système nerveux</term>
<term>Tomoscintigraphie</term>
<term>Tomographie par émission de positons</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Instabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SRULIJES (Karin)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>REIMOLD (Matthias)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LISCIC (Rajka M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BAUER (Sarah)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DIETZEL (Elisabeth)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LIEPELT-SCARFONE (Inga)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BERG (Daniela)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MAETZLER (Walter)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Nuclear Medicine and PET Center, University of Tuebingen</s1>
<s2>Tuebingen</s2>
<s3>DEU</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Robert-Bosch-Hospital, Department of Clinical Gerontology</s1>
<s2>Stuttgart</s2>
<s3>DEU</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>151-155</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508687520250</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0106517</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B24B07</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Ophtalmoplégie supranucléaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Supranuclear ophthalmoplegia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Oftalmoplejía supranuclear</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Instabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Instability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inestabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome oculomoteur</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Oculomotor syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Oculomotricidad síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'oeil</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Syndrome du tronc cérébral</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Brain stem syndrome</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Tallo encefalico sindrome</s0>
<s5>43</s5>
</fC07>
<fN21><s1>079</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 12-0106517 INIST</NO>
<ET>Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism</ET>
<AU>SRULIJES (Karin); REIMOLD (Matthias); LISCIC (Rajka M.); BAUER (Sarah); DIETZEL (Elisabeth); LIEPELT-SCARFONE (Inga); BERG (Daniela); MAETZLER (Walter)</AU>
<AF>Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen/Tuebingen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); German Center for Neurodegenerative Diseases, DZNE, University of Tuebingen/Tuebingen/Allemagne (1 aut., 3 aut., 4 aut., 5 aut., 6 aut., 7 aut., 8 aut.); Nuclear Medicine and PET Center, University of Tuebingen/Tuebingen/Allemagne (2 aut.); Robert-Bosch-Hospital, Department of Clinical Gerontology/Stuttgart/Allemagne (8 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2012; Vol. 27; No. 1; Pp. 151-155; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>Background: We hypothesized that postural instability and cognitive decline in patients with Richardson's syndrome could be a consequence of reduced thalamic and frontal metabolism. Severe Parkinsonian signs in patients with progressive supranuclear palsy-parkinsonism may be reflected by alterations in putaminal metabolism. Methods: Eleven patients with Richardson's syndrome, 8 patients with progressive supranuclear palsy-parkinsonism, 12 with Parkinson's disease, and 10 controls underwent clinical assessment and fluorodeoxyglucose positron emission tomography (PET). Results: Richardson's syndrome patients showed pronounced thalamic hypometabolism, and patients with progressive supranuclear palsy-parkinsonism pronounced putaminal hypometabolism, compared to all other investigated groups. The putamen/thalamus uptake ratio differentiated progressive supranuclear palsy-parkinsonism from Richardson's syndrome (area under the curve = 0.86) and from Parkinson's disease (area under the curve = 0.80) with acceptable accuracy. Frontal hypometabolism was predominantly found in Richardson's syndrome patients. Conclusions: Richardson's syndrome, progressive supranuclear palsy-parkinsonism and Parkinson's disease showed different metabolic patterns in fluorodeoxyglucose PET.</EA>
<CC>002B17; 002B24B07</CC>
<FD>Parkinsonisme; Pathologie du   système nerveux; Tomoscintigraphie; Tomographie par émission de positons; Ophtalmoplégie supranucléaire; Instabilité</FD>
<FG>Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du   système nerveux central; Syndrome du tronc cérébral</FG>
<ED>Parkinsonism; Nervous system diseases; Emission tomography; Positron emission tomography; Supranuclear ophthalmoplegia; Instability</ED>
<EG>Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome</EG>
<SD>Parkinson síndrome; Sistema nervioso patología; Tomocentelleografía; Tomografía emisión positrones; Oftalmoplejía supranuclear; Inestabilidad</SD>
<LO>INIST-20953.354000508687520250</LO>
<ID>12-0106517</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000293 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000293 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0106517
   |texte=   Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism

Fluorodeoxyglucose Positron Emission Tomography in Richardson's Syndrome and Progressive Supranuclear Palsy-Parkinsonism

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri